ImmuneInvestigational

VIP (Vasoactive Intestinal Peptide)

Intranasal, Intravenous, Subcutaneous injection

Overview

A 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts through VPAC1 and VPAC2 receptors to produce potent anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) and promoting regulatory T-cell differentiation.

Mechanism of Action

It also functions as a vasodilator, bronchodilator, and neuromodulator..

Research Summary & Key Findings

Clinical research by Dr. Shoemaker demonstrated efficacy in chronic inflammatory response syndrome (CIRS) associated with mold exposure. VIP nasal spray reduced markers of inflammation including TGF-beta-1, MMP-9, and C4a. Studies show neuroprotective effects and potential application in pulmonary hypertension and sarcoidosis.

Clinical Status

Investigational

VIP (Vasoactive Intestinal Peptide) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

IntranasalIntravenousSubcutaneous injection

Related Peptides in Immune

Find a Provider

Find a verified provider who offers VIP (Vasoactive Intestinal Peptide) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply VIP (Vasoactive Intestinal Peptide).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.